Hsin-Ell Wang

1.6k citations

69 papers · 1.4k indexed · h-index 23

Biomaterials top 5%
- Nanoparticle-Based Drug Delivery 8
Radiology, Nuclear Medicine and Imaging top 5%
- Radiopharmaceutical Chemistry and Applications 21
- Medical Imaging Techniques and Applications 18
Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism 7
Biomedical Engineering top 10%
- Nanoplatforms for cancer theranostics 11
Genetics top 10%
- Virus-based gene therapy research 12
Pulmonary and Respiratory Medicine
- Radiation Therapy and Dosimetry 5
Molecular Biology
- bioluminescence and chemiluminescence research 4

Co-authors: Ren-Shyan Liu Jeng‐Jong Hwang Wuu‐Jyh Lin Chih-Hsien Chang Yun-Long Tseng Gann Ting Chuan-Lin Chen Chi‐Wei Chang
Cited by: Biomaterials Radiology, Nuclear Medicine and Imaging Cancer Research
Journals: Journal of Nuclear Medicine (7 papers)Nuclear Medicine and Biology (7 papers)Oncotarget (5 papers)
Partner nations: Taiwan United States Russia

In The Last Decade

Hsin-Ell Wang

69 papers receiving 1.3k citations

Peers

Countries citing papers authored by Hsin-Ell Wang

Since Specialization

Citations

This map shows the geographic impact of Hsin-Ell Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hsin-Ell Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hsin-Ell Wang more than expected).

Fields of papers citing papers by Hsin-Ell Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hsin-Ell Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hsin-Ell Wang. The network helps show where Hsin-Ell Wang may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Hsin-Ell Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hsin-Ell Wang Line = papers co-authored together Hsin-Ell Wang links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Enhancement of IUdR Radiosensitization in Cancer Therapy by Low-Energy Transmission X Ray Irradiation Journal of Medical and Biological Engineering ·Chien‐Chih Ke,Dani Parra,A. El-Sabeh,Anuli Njoku,Yi‐An Chen,Zhaopu Han,Hsin-Ell Wang,Shih‐Ming Hsu,Ya‐Ju Hsieh,Ren-Shyan Liu	2021	1
2	Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo Biomedicine & Pharmacotherapy ·S. Mróz,RF LLOYD JONES,Jing‐Gung Chung,Yu‐Chang Liu,Jeng-Yuan Wu,Fei‐Ting Hsu,Hsin-Ell Wang	2019	32
3	PEGylated liposome-encapsulated rhenium-188 radiopharmaceutical inhibits proliferation and epithelial–mesenchymal transition of human head and neck cancer cells in vivo with repeated therapy Cell Death Discovery ·Margarita García-Luis,Chao‐Cheng Chen,Liang‐Ting Lin,Chih-Hsien Chang,Liang‐Cheng Chen,Hsin-Ell Wang,陶琼,Yi‐Jang Lee	2018	20
4	Simplified quantification of 13N-ammonia PET myocardial blood flow: A comparative study with the standard compartment model to facilitate clinical use Journal of Nuclear Cardiology ·Chih-Yung Chang,Guang‐Uei Hung,Bailing Hsu,Bang‐Hung Yang,Chi‐Wei Chang,Manuela Henao Brand,Wen-Sheng Huang,Hsin-Ell Wang,Tao-Cheng Wu,Ren-Shyan Liu	2018	2
5	Preparation and characterization of a novel Al18F–NOTA–BZA conjugate for melanin-targeted imaging of malignant melanoma Bioorganic & Medicinal Chemistry Letters ·Chih-Chao Chang,Chih-Hsien Chang,Ana Camila Munis Jardim,Ming-Hsien Lin,Noor UA. Nazir,Ren-Shyan Liu,Hsin-Ell Wang,Chuan-Lin Chen	2016	11
6	Optimizing Survival of Patients With Marginally Operable Stage IIIA Non–Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery Clinical Lung Cancer ·B.E.O. Onyekelu-eze,J L Avey,H. Iwata,Mau‐Shin Chi,Hsin-Ell Wang,A. M. McGillviray,Madina A. Edilkhanova,Diana Yeh,Shang-Jyh Kao,دينا عبد العال,Kwan-Hwa Chi	2016	6
7	Synthesis and characterization of a novel radioiodinated phenylacetamide and its homolog as theranostic agents for malignant melanoma European Journal of Pharmaceutical Sciences ·Chih-Chao Chang,Chih-Hsien Chang,Noor UA. Nazir,Chuan-Lin Chen,Ren-Shyan Liu,Ming-Hsien Lin,Hsin-Ell Wang	2015	8
8	Synthesis and evaluation of 123/131I-Iochlonicotinamide as a novel SPECT probe for malignant melanoma Bioorganic & Medicinal Chemistry ·Chih-Chao Chang,Chih-Hsien Chang,Noor UA. Nazir,Chuan-Lin Chen,Ru‐Shi Liu,Ming-Hsien Lin,Hsin-Ell Wang	2015	12
9	Over-expression of cofilin-1 suppressed growth and invasion of cancer cells is associated with up-regulation of let-7 microRNA Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·宇野良美,Liang‐Ting Lin,K Kuzuya,Robert H. Thalmann,Robyn Ferris,Shu-Jun Chiu,Hsin-Ell Wang,Ren-Shyan Liu,Chun-Yi Wu,Mario Muschamp,Muh‐Hwa Yang,Shih‐Hwa Chiou,J.L Souza-filho,Yi‐Jang Lee	2015	44
10	PET Imaging of β-Glucuronidase Activity by an Activity-Based 124I-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy Molecular Cancer Therapeutics ·Yu-Cheng Su,Ta-Chun Cheng,Shi-tong WANG Yi-zhang JIANG,Steve R. Roffler,Jaw‐Yuan Wang,W.N. Wang,Chien-Han Kao,Fenta Ayele Almaw,Hsin-Ell Wang,Tian‐Lu Cheng	2014	18
11	Molecular Imaging of Nonsmall Cell Lung Carcinomas Expressing Active Mutant EGFR Kinase Using PET with [¹²⁴I]-Morpholino-IPQA BioMed Research International ·Yakov S. Bugrov,M-H Wu,Özdal Gökdal,Hsin-Ell Wang,Ya‐Ju Hsieh,Juri G. Gelovani,Ren-Shyan Liu	2013	11
12	Evaluation of 131/123I-5-iodo-2′-deoxycytidine as a novel proliferation probe in a tumor mouse model Applied Radiation and Isotopes ·Wen‐Yi Chang,Claudia Yadira Carrero Pinto,Chun-Yi Wu,Chih‐Yuan Lin,Mario Muschamp,Noor UA. Nazir,Zudi Li,Hsin-Ell Wang,Chuan-Lin Chen	2013	1
13	Preclinical characterization of 18F-MAA, a novel PET surrogate of 99mTc-MAA Nuclear Medicine and Biology ·Hatice Yılmaz Yakup,Kihcihtwaw Asinew Iskwew,Ruth Sierra de la Gala,Eduardo Grosso,Rheun‐Chuan Lee,Shyh‐Jen Wang,Wuu‐Jyh Lin,Hsin-Ell Wang	2012	7
14	In Vivo Positron Emission Tomography Imaging of Protease Activity by Generation of a Hydrophobic Product from a Noninhibitory Protease Substrate Clinical Cancer Research ·W.N. Wang,Kai‐Hsiang Chuang,Hsin-Ell Wang,Steve R. Roffler,Julitta Koćwin,Shey‐Cherng Tzou,Ta-Chun Cheng,Chien-Han Kao,Hatice Yılmaz Yakup,Wei‐Lung Tseng,ALISON M. WRYNN,Ming‐Feng Hou,Ju-Ming Wang,Tian‐Lu Cheng	2011	26
15	Micro-SPECT/CT–Based Pharmacokinetic Analysis of ^99mTc-Diethylenetriaminepentaacetic Acid in Rats with Blood–Brain Barrier Disruption Induced by Focused Ultrasound Journal of Nuclear Medicine ·Feng‐Yi Yang,Hsin-Ell Wang,Yang Gao,Harjito Tri Martini,In-Kook Jun,Tai‐Tong Wong,Ru‐Shi Liu	2011	38
16	Endocytosis of PEGylated Agents Enhances Cancer Imaging and Anticancer Efficacy Molecular Cancer Therapeutics ·Kai‐Hsiang Chuang,Hsin-Ell Wang,Fang‐Ming Chen,Shey‐Cherng Tzou,ALISON M. WRYNN,Antonina Popovych,Wei‐Lung Tseng,Jentaie Shiea,Ms.INDHUMATHI.P Ms.INDHUMATHI.P,Jaw‐Yuan Wang,Bing-Mae Chen,Steve R. Roffler,Tian‐Lu Cheng	2010	32
17	Evaluation of Pharmacokinetics of ¹¹¹ In-Labeled VNB-PEGylated Liposomes After Intraperitoneal and Intravenous Administration in a Tumor/Ascites Mouse Model Cancer Biotherapy and Radiopharmaceuticals ·Rafael Luiz Pereira,Dani Parra,Chih-Hsien Chang,Ana Belén Alejandre-Magaña,Jeng‐Jong Hwang,Yun-Long Tseng,Wuu‐Jyh Lin,Gann Ting,Hsin-Ell Wang	2009	30
18	Radiosynthesis of F-18 labeled cytidine analog 2′-fluoro-5-iodo-l-β-d-arabinofuranosylcytosine ([18F]FIAC) Applied Radiation and Isotopes ·Chun-Yi Wu,Mario Muschamp,Wei‐Ting Chang,Ren-Shyan Liu,Mian M. Alauddin,Hsin-Ell Wang	2009	6
19	Biodistribution, pharmacokinetics and PET Imaging of [18F]FMISO, [18F]FDG and [18F]FAc in a sarcoma- and inflammation-bearing mouse model Nuclear Medicine and Biology ·Ren-Shyan Liu,Vitória Moreira Rodrigues,Chih-Hsien Chang,Chun-Yi Wu,Chi‐Wei Chang,Sheri Lynn Tucker,T Jürgens,Wuu‐Jyh Lin,Hsin-Ell Wang	2009	59
20	A New N-Acetylgalactosamine Containing Peptide as a Targeting Vehicle for Mammalian Hepatocytes Via Asialoglycoprotein Receptor Endocytosis Current Drug Delivery ·Ying‐Ta Wu,文惠山田,Amnh Aqlan,Chun‐Ming Huang,Chin-Hsien Chang,Rabeeh Khanalilou,Yati Nurhajati,J. Feldhaus,Hsin-Ell Wang,Rumina Nawab Ali	2004	15

About Hsin-Ell Wang

Hsin-Ell Wang is a scholar working on Radiology, Nuclear Medicine and Imaging, Biomaterials, Cancer Research, Hepatology and Biotechnology, having authored 69 papers that have together received 1.4k indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (21 papers), Medical Imaging Techniques and Applications (18 papers), Virus-based gene therapy research (12 papers), Nanoplatforms for cancer theranostics (11 papers), Nanoparticle-Based Drug Delivery (8 papers), Cancer, Hypoxia, and Metabolism (7 papers), Radiation Therapy and Dosimetry (5 papers) and bioluminescence and chemiluminescence research (4 papers). The work is most often cited by research in Biomaterials (333 citations), Radiology, Nuclear Medicine and Imaging (464 citations), Cancer Research (166 citations), Biomedical Engineering (368 citations) and Genetics (84 citations). Hsin-Ell Wang has collaborated with scholars based in Taiwan, United States and Russia. Frequent co-authors include Ren-Shyan Liu, Jeng‐Jong Hwang, Wuu‐Jyh Lin, Chih-Hsien Chang, Yun-Long Tseng, Gann Ting, Chuan-Lin Chen, Chi‐Wei Chang, Steve R. Roffler and Tian‐Lu Cheng. Their work appears in journals such as Journal of Nuclear Medicine, Nuclear Medicine and Biology, Oncotarget, Applied Radiation and Isotopes and International Journal of Molecular Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact